Browse > Article

Imaging Hypoxic Myocardium  

Bae, Sang-Kyun (Department of Nuclear Medicine, Inje University College of Medicine)
Publication Information
The Korean Journal of Nuclear Medicine / v.39, no.2, 2005 , pp. 141-145 More about this Journal
Abstract
Hypoxia (decreased tissue oxygen tension) is a component of many diseases such as tumors, cerebrovascular diseases and ischemic heart diseases. Although hypoxia can be secondary to a low inspired $pO_2$ or a variety of lung disorders, the most common cause is ischemia due to an oxygen demand greater than the local oxygen supply. In the heart tissue, hypoxia is often observed in persistent low-flow states, such as hibernating myocardium. Direct "hot spot" imaging of myocardial tissue hypoxia is potentially of great clinical importance because it may provide a means of identifying dysfunctional chronically ischemic but viable hibernating myocardium. A series of radiopharmaceuticals that incorporate nitroimidazole moieties have been synthesized to detect decreased local tissue pO2. In contrast to agents that localize in proportion to perfusion, these agents concentrate in hypoxic tissue. However, the ideal agents are not developed yet and the progress is very slow. Furthermore, the research focus is on tumor hypoxia nowadays. This review introduces the myocardial hypoxia imaging with summarizing the development of radiopharmaceuticals.
Keywords
hypoxia; nitroimidazole; hibernating myocardium;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer 1981;43:546-50   DOI   PUBMED   ScienceOn
2 Grunbaum Z, Freauff SJ, Krohn KA, Wilbur DS, Magee S, Rasey JS. Synthesis and characterization of congeners of misonidazole for imaging hypoxia. J Nucl Med 1987;28:68-75   PUBMED
3 Rasey JS, Koh WJ, Grierson JR, Grunbaum Z, Krohn KA. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys 1989;17:985-91   DOI   PUBMED   ScienceOn
4 Martin GV, Caldwell JH, Rasey JS, Grunbaum Z, Cerqueira M, Krohn KA. Enhanced binding of the hypoxic cell marker $[^3H]$fluoromisonidazole in ischemic myocardium. J Nucl Med 1989;30:194-201   PUBMED
5 Caldwell JH, Revenaugh JR, Martin GV, Johnson PM, Rasey JS, Krohn KA. Comparison of fluorine-18-fluorodeoxyglucose and tritiated fluoromisonidazole uptake during low-flow ischemia. J Nucl Med 1995;36:1633-8
6 Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 1995;2:437-45   DOI   ScienceOn
7 Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med 1997;38:1155-60
8 Sinusas AJ. The potential for myocardial imaging with hypoxia markers. Semin Nucl Med 1999;29:330-8   DOI   PUBMED   ScienceOn
9 Ballinger JR, Kee JW, Rauth AM. In vitro and in vivo evaluation of a technetium-99m-labeled 2-nitroimidazole (BMS181321) as a marker of tumor hypoxia. J Nucl Med 1996;37:1023-31
10 Stone CK, Mulnix T, Nickles RJ, Renstrom B, Nellis SH, Liedtke AJ, et al. Myocardial kinetics of a putative hypoxic tissue marker, $^{99m}Tc$-labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion. Circulation 1995;92:1246-53   DOI   PUBMED   ScienceOn
11 Shelton ME, Dence CS, Hwang DR, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: A marker of hypoxic myocardium. J Nucl Med 1989;30:351-8   PUBMED
12 Martin GV, Cerqueira MD, Caldwell JH, Rasey JS, Embree L, Krohn KA. Fluoromisonidazole. A metabolic marker of myocyte hypoxia. Circ Res 1990;67:240-4   DOI   PUBMED   ScienceOn
13 Shelton ME, Dence CS, Hwang DR, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: A potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990;16:477-85   DOI   PUBMED
14 Linder KE, Chan YW, Cyr JE, Nowotnik DP, Eckelman WC, Nunn AD. Synthesis, characterization, and in vitro evaluation of nitroimidazole--BATO complexes: New technetium compounds designed for imaging hypoxic tissue. Bioconjug Chem 1993;4: 326-33   DOI   ScienceOn
15 Johnson LL, Schofield L, Donahay T, Mastrofrancesco P. Myocardial uptake of a $^{99m}Tc$-nitroheterocycle in a swine model of occlusion and reperfusion. J Nucl Med 2000;41:1237-43   PUBMED
16 Johnson LL, Schofield L, Mastrofrancesco P, Donahay T, Nott L. Technetium-99m-nitroimadazole uptake in a swine model of demand ischemia. J Nucl Med 1998;39:1468-75
17 Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res 1987;111:292-304   DOI   ScienceOn
18 Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995;22:265-80   DOI   ScienceOn
19 Grierson JR, Link JM, Mathis CA, Rasey JS, Krohn KA. A radiosynthesis of fluorine-18 fluoromisonidazole. J Nucl Med 1989;30:343-50   PUBMED
20 Ng CK, Sinusas AJ, Zaret BL, Soufer R. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. Circulation 1995;92:1261-8   DOI   PUBMED   ScienceOn
21 Linder KE, Chan YW, Cyr JE, Malley MF, Nowotnik DP, Nunn AD. TcO(PnA.O-1-(2-nitroimidazole)) [BMS-181321], a new technetium-containing nitroimidazole complex for imaging hypoxia: Synthesis, characterization, and xanthine oxidase-catalyzed reduction. J Med Chem 1994;37:9-17   DOI   ScienceOn
22 Franko AJ. Misonidazole and other hypoxia markers: Metabolism and applications. Int J Radiat Oncol Biol Phys 1986;12:1195-202   DOI   PUBMED   ScienceOn
23 Jette DC, Wiebe LI, Chapman JD. Synthesis and in vivo studies of the radiosensitizer $4-[^{82}br]$bromomisonidazole. Int J Nucl Med Biol 1983;10:205-10   DOI   ScienceOn
24 Shi CQ, Sinusas AJ, Dione DP, Singer MJ, Young LH, Heller EN, et al. Technetium-99m-nitroimidazole (BMS181321): A positive imaging agent for detecting myocardial ischemia. J Nucl Med 1995;36:1078-86   PUBMED
25 Okada RD, Johnson G, 3rd, Nguyen KN, Liu Z, Edwards B, Archer CM, et al. $^{99m}Tc$-HL91: 'hot spot' detection of ischemic myocardium in vivo by gamma camera imaging. Circulation 1998;97:2557-66   DOI   PUBMED   ScienceOn
26 Webster L. Drugs used in chemotherapy of protozoal infections. In: Gilman A, Rail T, Nies A, Taylor P, eds. The pharmacological basis of therapeutics. New York: Pergamon Press, 1990:1002-4
27 Berne R, Levy M. Skeletal physiology. In: Berne R, Levy M, eds. Physiology. St. Louis: Mosby Yearbook, 1993:292-308
28 Jerabek PA, Patrick TB, Kilbourn MR, Dischino DD, Welch MJ. Synthesis and biodistribution of $^{18}F$-labeled fluoronitroimidazoles: Potential in vivo markers of hypoxic tissue. Int J Rad Appl Instrum [A] 1986;37:599-605   DOI   ScienceOn